Tenaya Therapeutics, Inc.
TNYA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.05 | -0.01 | -0.14 |
| FCF Yield | -75.46% | -43.21% | -138.80% | -10.98% |
| EV / EBITDA | -1.27 | -1.68 | -0.09 | -11.03 |
| Quality | ||||
| ROIC | -108.62% | -86.25% | -47.82% | -24.56% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.81 | 0.82 | 0.84 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 11.41% | 17.39% | -45.53% | -90.08% |
| Safety | ||||
| Net Debt / EBITDA | -0.09 | 0.27 | 0.70 | 0.36 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.44 | 0.00 |
| Cash Conversion Cycle | 0.00 | -236.55 | -1,236.89 | -972.21 |